Anthropic, OpenAI, and Google DeepMind team up to build guardrails around AI-powered biology

The same AI systems that can design life-saving drugs can, in theory, design the opposite. Anthropic, OpenAI, and Google DeepMind have decided to get ahead of that problem before it becomes a crisis. The three dominant AI labs are rolling out a suite of safety measures targeting biological applications of their models, from drug discovery and disease research to pandemic preparedness. The coordinated push includes real-time content classifiers, vetted researcher access programs, and extensive red teaming, all designed to let the good science through while slamming the door on bioweapons research. A public letter and a line in the sand In June 2026, the CEOs of all three companies signed a public letter directed at US lawmakers. The message was blunt: synthetic DNA and RNA providers need mandatory screening and recordkeeping requirements, because AI is making it significantly easier to design dangerous biological agents. Google DeepMind moved first on a concrete program. On July 16, the company announced its bioresilience initiative, which pairs trusted researchers with rapid-deployment drug design engines. DeepMind’s approach leans heavily on its Isomorphic Labs subsidiary, which h...